Can CMR elucidate the cardiovascular benefit of SGLT2 inhibitors?

Simple item page
dc.contributor.authorNicholls, S.J.
dc.contributor.authorNerlekar, N.
dc.date.issued2021
dc.description.abstractAbstract not available
dc.description.statementofresponsibilityStephen J. Nicholls, Nitesh Nerlekar
dc.identifier.citationJACC Cardiovascular Imaging, 2021; 14(6):1174-1176
dc.identifier.doi10.1016/j.jcmg.2020.11.003
dc.identifier.issn1936-878X
dc.identifier.issn1876-7591
dc.identifier.orcidNicholls, S.J. [0000-0002-9668-4368]
dc.identifier.urihttp://hdl.handle.net/2440/131376
dc.language.isoen
dc.publisherElsevier
dc.rights© 2021 by The American College of Cardiology Foundation published by Elsevier
dc.source.urihttps://doi.org/10.1016/j.jcmg.2020.11.003
dc.subjectCMR
dc.subjectSGLT2 inhibitors
dc.subjectcardiovascular
dc.subjectclinical trials
dc.subjectinterstitial
dc.titleCan CMR elucidate the cardiovascular benefit of SGLT2 inhibitors?
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications